⌘K
Loading ticker…
As of 2026-08-26, Arcutis Biotherapeutics, Inc. Common Stock (ARQT) has a 3-month relative strength percentile of 80 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 54. The current market Stance is 50.1 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 4.5%, relative volume 1.09×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
ARQT appears in 1 ETF as of Jun 2026: PSC at 0.19% weight, $5M notional.
Held by 56 ETFs · $372M across latest filings · largest weight 1.28% (BBP).
Top 1 by value, from SEC N-PORT-P filings dated Jun 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| PSC | 0.19% | $5M | −0.02 pp |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARQT Jan avg: 19.03% median: 3.50% win: 50% σ: 43.05% n: 4 2022-04-12 → 2026-07-31 | ARQT Feb avg: 20.62% median: 4.85% win: 75% σ: 36.52% n: 4 2022-04-12 → 2026-07-31 | ARQT Mar avg: -8.50% median: -8.12% win: 25% σ: 19.25% n: 4 2022-04-12 → 2026-07-31 | ARQT Apr avg: 0.17% median: -2.84% win: 20% σ: 15.46% n: 5 2022-04-12 → 2026-07-31 | ARQT May avg: -12.39% median: -7.58% win: 40% σ: 19.69% n: 5 2022-04-12 → 2026-07-31 | ARQT Jun avg: 13.98% median: 11.24% win: 100% σ: 10.31% n: 5 2022-04-12 → 2026-07-31 | ARQT Jul avg: 8.61% median: 8.28% win: 100% σ: 5.51% n: 5 2022-04-12 → 2026-07-31 | ARQT Aug avg: 0.96% median: 7.25% win: 75% σ: 15.25% n: 4 2022-04-12 → 2026-07-31 (current) | ARQT Sep avg: -14.99% median: -21.81% win: 25% σ: 26.13% n: 4 2022-04-12 → 2026-07-31 | ARQT Oct avg: -10.37% median: -9.06% win: 25% σ: 37.57% n: 4 2022-04-12 → 2026-07-31 | ARQT Nov avg: 14.31% median: 9.28% win: 50% σ: 32.68% n: 4 2022-04-12 → 2026-07-31 | ARQT Dec avg: 15.75% median: 0.79% win: 50% σ: 40.77% n: 4 2022-04-12 → 2026-07-31 |